Transform Your Future: Ace the 2026 Certified Diabetes Educator Exam!

Sitagliptin is recognized as a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, which is a class of medications used to manage blood sugar levels in individuals with type 2 diabetes. DPP-4 inhibitors work by blocking the action of the DPP-4 enzyme that is involved in the breakdown of incretin hormones. These hormones help regulate glucose metabolism by increasing insulin production and decreasing glucagon secretion when blood glucose levels are elevated. By inhibiting DPP-4, sitagliptin enhances the body’s natural response to meals, leading to better glycemic control.

Other options listed do not fall under the category of DPP-4 inhibitors. Acarbose is an alpha-glucosidase inhibitor, which works by delaying carbohydrate absorption in the intestines. Exenatide is a GLP-1 receptor agonist that mimics incretin to increase insulin secretion in response to meals but does not inhibit DPP-4. Repaglinide is a meglitinide that stimulates insulin release from the pancreas but operates through a different mechanism than DPP-4 inhibitors. Thus, sitagliptin stands out as the correct answer within this context.